المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, Galamaga, Rob

المصدر: ENT and Skull Base Surgery

مصطلحات موضوعية: Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Everolimus, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Sunitinib, Survival Analysis

الوصف: BACKGROUND: Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. RESULTS: A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P CONCLUSIONS: Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

العلاقة: https://scholar.barrowneuro.org/ent-and-skull-base-surgery/23Test

الإتاحة: https://doi.org/10.1056/NEJMoa2035716Test
https://scholar.barrowneuro.org/ent-and-skull-base-surgery/23Test

المؤلفون: Solis-Hernandez, Mª Pilar, Fernandez Del Valle, Ana, Carmona-Bayonas, Alberto, Garcia-Carbonero, Rocio, Custodio, Ana, Benavent, Marta, Alonso Gordoa, Teresa, Nuñez-Valdovino, Bárbara, Sanchez Canovas, Manuel, Matos, Ignacio, Alonso, Vicente, Lopez, Carlos, Viudez, Antonio, Izquierdo, Marta, Calvo-Temprano, David, Grande, Enrique, Capdevila, Jaume, Jimenez-Fonseca, Paula

مصطلحات موضوعية: Adult, Aged, 80 and over, Antineoplastic Agents, Confidence Intervals, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors, Pancreatic Neoplasms, Progression-Free Survival, Proportional Hazards Models, Prospective Studies, Response Evaluation Criteria in Solid Tumors, Sunitinib, Tomography, X-Ray Computed, Tumor Burden, Young Adult

الوصف: The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/14466Test; PMC6889276; https://www.nature.com/articles/s41416-019-0558-7.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889276/pdfTest

الإتاحة: https://doi.org/10.1038/s41416-019-0558-7Test
http://hdl.handle.net/10668/14466Test
https://www.nature.com/articles/s41416-019-0558-7.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889276/pdfTest

المؤلفون: Carmona-Bayonas, Alberto, Jiménez-Fonseca, Paula, Lamarca, Ángela, Barriuso, Jorge, Castaño, Ángel, Benavent, Marta, Alonso, Vicente, Riesco-Martínez, María del Carmen, Alonso-Gordoa, Teresa, Custodio, Ana, Sánchez Cánovas, Manuel, Hernando Cubero, Jorge, López, Carlos, Lacasta, Adelaida, Fernández Montes, Ana, Marazuela, Mónica, Crespo, Guillermo, Escudero, Pilar, Diaz, José Ángel, Feliciangeli, Eduardo, Gallego, Javier, Llanos, Marta, Segura, Ángel, Vilardell, Felip, Percovich, Juan Carlos, Grande, Enrique, Capdevila Castillón, Jaume, Valle, Juan W., García-Carbonero, Rocío, Universitat Autònoma de Barcelona

المساهمون: LEO Pharma, Ipsen, Pfizer, Roche, Amgen, Merck & Co, Merck Sharp & Dohme, AstraZeneca, Sanofi, Bayer, Eisai, Celgene, Novartis, Advanced Accelerator Applications, Bristol-Myers Squibb, UAM. Departamento de Medicina, Novartis Farmaceútica

المصدر: JOURNAL OF CLINICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Digital.CSIC. Repositorio Institucional del CSIC
Biblos-e Archivo. Repositorio Institucional de la UAM
Carmona-bayonas, A, Jiménez-fonseca, P, Lamarca, Á, Barriuso, J, Castaño, Á, Benavent, M, Alonso, V, Riesco-martínez, M D C, Alonso-gordoa, T, Custodio, A, Sánchez Cánovas, M, Hernando Cubero, J, López, C, Lacasta, A, Fernández Montes, A, Marazuela, M, Crespo, G, Escudero, P, Diaz, J Á, Feliciangeli, E, Gallego, J, Llanos, M, Segura, Á, Vilardell, F, Percovich, J C, Grande, E, Capdevila, J, Valle, J W & García-carbonero, R 2019, ' Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study ', Journal of Clinical Oncology, pp. JCO.19.00980 . https://doi.org/10.1200/JCO.19.00980Test
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Journal of Clinical Oncology
Repisalud
Instituto de Salud Carlos III (ISCIII)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Octreotide, Neuroendocrine tumors, Lanreotide, THERAPY, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, PROGNOSTIC-FACTORS, EVEROLIMUS, Gastrointestinal Cancer, prognostic model, Manchester Cancer Research Centre, ORIGINAL REPORTS, somatostatin analogs, Progression-Free Survival, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Female, lanreotide, Somatostatin, medicine.drug, Cohort study, NEOPLASMS, Adult, medicine.medical_specialty, Adolescent, Medicina, SUNITINIB, nomogram, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Progression-free survival, Survival analysis, Retrospective Studies, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Retrospective cohort study, Nomogram, medicine.disease, Survival Analysis, Hormones, MODEL, 030104 developmental biology, chemistry, REGISTRY, business, octreotide

الوصف: [Purpose] Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients.
[Patient and methods] We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom).
[Results] We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively.
[Conclusion] The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a valuable tool for making treatment decisions in daily clinical practice.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abca4a41dc814f6e3652d2060787a26Test
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7071Test